These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17323590)

  • 21. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
    Turpie AG
    Int J Clin Pract; 2004 May; 58(5):483-93. PubMed ID: 15206506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Apr; 3(4):455-7. PubMed ID: 11934350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.
    Lundkvist J; Bergqvist D; Jönsson B
    Eur J Health Econ; 2007 Dec; 8(4):313-23. PubMed ID: 17225129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for extended prophylaxis in the setting of orthopedic surgery.
    Dobesh PP
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):73S-81S. PubMed ID: 15317402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
    Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
    N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
    Turpie AG; Eriksson BI; Bauer KA; Lassen MR
    Chest; 2003 Dec; 124(6 Suppl):371S-378S. PubMed ID: 14668420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylaxis for thromboembolism in hospitalized medical patients.
    Famularo G; Minisola G; De Simone C
    N Engl J Med; 2007 Jul; 357(3):305; author reply 305-6. PubMed ID: 17644834
    [No Abstract]   [Full Text] [Related]  

  • 29. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis of venous thromboembolism in medical patients.
    Gerotziafas GT; Samama MM
    Curr Opin Pulm Med; 2004 Sep; 10(5):356-65. PubMed ID: 15316432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
    Bauer KA
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
    Comp PC
    Pharmacotherapy; 2003 Jun; 23(6):772-87. PubMed ID: 12820819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
    Rostagno C
    Cardiovasc Hematol Disord Drug Targets; 2016; 15(3):204-9. PubMed ID: 26721520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomics of thrombosis management.
    Hawkins D
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
    Raskob GE; Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fondaparinux for thrombosis prevention after orthopaedic surgery: a revolution?].
    Monreal M
    Med Clin (Barc); 2003 May; 120(20):775-6. PubMed ID: 12797930
    [No Abstract]   [Full Text] [Related]  

  • 40. Fondaparinux: a new antithrombotic agent.
    Cheng JW
    Clin Ther; 2002 Nov; 24(11):1757-69; discussion 1719. PubMed ID: 12501872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.